Is the price of generic drugs of neratinib/neratinib really reduced significantly?

The price of generic drugs of Neratinib/Neratinib has indeed dropped significantly compared with the original drug. This trend is mainly due to the rapid development of the generic drug industry in many developing countries and the gradual loosening of patent period restrictions. The original drug neratinib, developed by Puma Biotechnology, is priced extremely high in overseas markets. In the United States, Canada, Europe and other regions, its price per box of 40 mg × 180 tablets is often more than US$10,000, which is a huge financial burden for patients who are not included in the medical insurance reimbursement system. Even though the drug has been included in the Category B National Medical Insurance List in China, the out-of-pocket cost is still high, limiting the medication options for some patients.

In contrast, the generic version of neratinib has shown strong competitiveness in terms of price. For example, companies such as Yaopin International Pharmaceuticals in Bangladesh have launched generic versions of neratinib that meet international quality standards. The price is usually controlled between RMB 2,000 and 3,000, and the same specification is 40 mg × 180 tablets. This price level is equivalent to about one-tenth of the overseas selling price of the original drug. Even compared with the cost after domestic medical insurance payment, it has certain advantages, greatly improving the accessibility and continuity of treatment for patients with limited economic conditions.

However, it should be pointed out that although these generic drugs are highly consistent with the original drugs in terms of chemical composition, dosage and basic efficacy, they still have differences in bioequivalence, long-term safety data and regulatory certification. For example, most generic drugs have not obtained marketing approval from China’s State Food and Drug Administration, and therefore cannot be purchased through regular hospital channels. Patients mostly obtain them through cross-border drug purchases. Although this method can be used as an affordable alternative, it also brings potential risks such as the credibility of drug sources, quality consistency, and lack of medication guidance.

Reference materials:https://en.wikipedia.org/wiki/Neratinib